Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage.

adjuvant radiotherapy postoperative radiotherapy prostate cancer radiotherapy salvage radiotherapy

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
12 Sep 2022
Historique:
received: 22 07 2022
revised: 05 09 2022
accepted: 07 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Results of three randomized clinical trials (RCTs) comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) of prostate carcinoma and a subsequent meta-analysis of the individual patient data from these RCTs were recently published. The results suggest that early eSRT is as effective and potentially less toxic than ART. Therefore, eSRT should be considered the standard of care. However, due to limitations in the RCTs, ART remains a valid treatment option in patients with the combination of high-risk features such as Gleason Score (GS) 8-10, positive surgical margins (R1) and pathological T-stage 3 or 4 (pT3/4). This article provides a critical appraisal of the RCTs and the rationale for recommendations adopted in the current national guidelines regarding patients with high-risk features after radical prostatectomy (RP): ART should be offered in case of pT3/pT4 and R1 and Gleason Score 8-10; ART can be offered in case of pT3/pT4 and R0 and Gleason Score 8-10 as well as in case of multifocal R1 (including pT2) and Gleason Score 8-10. In any case, the alternative treatment option of eSRT in case of rising PSA should be discussed with the patient.

Identifiants

pubmed: 36140357
pii: biomedicines10092256
doi: 10.3390/biomedicines10092256
pmc: PMC9496034
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Urol. 2009 Mar;181(3):956-62
pubmed: 19167731
Lancet. 2021 May 1;397(10285):1623
pubmed: 33933203
Eur Urol. 2019 Nov;76(5):586-595
pubmed: 31375279
Eur Urol. 2013 Aug;64(2):193-8
pubmed: 23522911
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
J Clin Oncol. 2021 Jul 10;39(20):2284-2293
pubmed: 34086480
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Eur Urol Oncol. 2022 Jun;5(3):304-313
pubmed: 34016556
Lancet Oncol. 2020 Oct;21(10):1331-1340
pubmed: 33002437
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):839-843
pubmed: 33610298
Lancet. 2020 Oct 31;396(10260):1413-1421
pubmed: 33002429
Acta Oncol. 2018 Mar;57(3):362-367
pubmed: 28816074
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
Lancet. 2020 Oct 31;396(10260):1374-1375
pubmed: 33002430

Auteurs

Daniel Wegener (D)

Department of Radiation Oncology, University Hospital Tuebingen, 72076 Tuebingen, Germany.

Daniel M Aebersold (DM)

Department of Radiation Oncology, Inselspital Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Marc-Oliver Grimm (MO)

Department of Urology, Jena University Hospital, 07743 Jena, Germany.

Peter Hammerer (P)

Department of Urology, University Hospital Braunschweig, 38106 Braunschweig, Germany.

Michael Froehner (M)

Department of Urology, Zeisigwaldkliniken Bethanien Chemnitz, 09130 Chemnitz, Germany.

Markus Graefen (M)

Martini Clinic, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Dirk Boehmer (D)

Department of Radiation Oncology, Charité University Medicine Berlin, 10117 Berlin, Germany.

Daniel Zips (D)

Department of Radiation Oncology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
German Cancer Consortium (DKTK), Partner Site Tuebingen, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Thomas Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, 89081 Ulm, Germany.

Classifications MeSH